Literature DB >> 7501441

Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent.

L Benimetskaya1, J L Tonkinson, M Koziolkiewicz, B Karwowski, P Guga, R Zeltser, W Stec, C A Stein.   

Abstract

Antisense oligodeoxynucleotides can selectively inhibit the expression of individual genes and thus have potential applications in anticancer and antiviral therapy. A critical prerequisite to their use as therapeutic agents is the understanding of their non-specific interactions with biological structures, e.g. proteins. In this study we examined the interactions of P-chiral phosphorothioate oligodeoxynucleotides with several proteins. The Rp- and Sp- diastereomers, and racemic machine-made mixtures, or M-oligodeoxynucleotides were used independently as competitors of the binding of a probe, phosphodiester oligodeoxynucleotide bearing a 5' alkylating moiety, to rsCD4, bFGF and laminin. These oligodeoxynucleotides were also used as competitors of the binding of a non-alkylating probe M-phosphorothioate oligodeoxynucleotide, 5'-32P-SdT18 to fibronectin. The average values of and quantitative estimates for the IC50 of competition and the constant of competition (Kc) of Rp-, Sp- and M-stereoisomers of several homo- and heteropolymer oligodeoxynucleotides were determined and compared. Surprisingly, in the proteins we studied, the values of IC50 and Kc for the Rp-, Sp- and M-oligodeoxynucleotides were essentially identical. Thus, the ability of the phosphorothioate oligodeoxynucleotides we employed, to bind to the proteins studied in this work, is virtually independent of P-chirality. Our results also imply that the role of the purine and pyrimidine bases in oligodeoxynucleotide-protein interactions, as well as the nature of the contact points (sulfur versus oxygen) between the oligomer and the protein, may be relatively unimportant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7501441      PMCID: PMC307375          DOI: 10.1093/nar/23.21.4239

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  13 in total

1.  Application of phosphate-backbone-modified oligonucleotides in the studies on EcoRI endonuclease mechanism of action.

Authors:  M Koziolkiewicz; W J Stec
Journal:  Biochemistry       Date:  1992-10-06       Impact factor: 3.162

2.  Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates).

Authors:  W J Stec; A Grajkowski; M Koziolkiewicz; B Uznanski
Journal:  Nucleic Acids Res       Date:  1991-11-11       Impact factor: 16.971

Review 3.  Nucleotide and oligonucleotide derivatives as enzyme and nucleic acid targeted irreversible inhibitors. Chemical aspects.

Authors:  D G Knorre; V V Vlassov; V F Zarytova; G G Karpova
Journal:  Adv Enzyme Regul       Date:  1985

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Synthesis of d(GC) and d(CG) octamers containing alternating phosphorothioate linkages: effect of the phosphorothioate group on the B-Z transition.

Authors:  R Cosstick; F Eckstein
Journal:  Biochemistry       Date:  1985-07-02       Impact factor: 3.162

6.  Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120.

Authors:  C A Stein; A M Cleary; L Yakubov; S Lederman
Journal:  Antisense Res Dev       Date:  1993

7.  Abasic oligodeoxyribonucleoside phosphorothioates: synthesis and evaluation as anti-HIV-1 agents.

Authors:  R P Iyer; B Uznanski; J Boal; C Storm; W Egan; M Matsukura; S Broder; G Zon; A Wilk; M Koziolkiewicz
Journal:  Nucleic Acids Res       Date:  1990-05-25       Impact factor: 16.971

Review 8.  Antisense oligonucleotides as therapeutic agents--is the bullet really magical?

Authors:  C A Stein; Y C Cheng
Journal:  Science       Date:  1993-08-20       Impact factor: 47.728

9.  Physicochemical properties of phosphorothioate oligodeoxynucleotides.

Authors:  C A Stein; C Subasinghe; K Shinozuka; J S Cohen
Journal:  Nucleic Acids Res       Date:  1988-04-25       Impact factor: 16.971

10.  Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity.

Authors:  Z Khaled; D Rideout; K R O'Driscoll; D Petrylak; A Cacace; R Patel; L C Chiang; S Rotenberg; C A Stein
Journal:  Clin Cancer Res       Date:  1995-01       Impact factor: 12.531

View more
  15 in total

1.  Radiolabeled oligonucleotides for antisense imaging.

Authors:  Arun K Iyer; Jiang He
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

2.  CD, absorption and thermodynamic analysis of repeating dinucleotide DNA, RNA and hybrid duplexes [d/r(AC)]12.[d/r(GT/U)]12 and the influence of phosphorothioate substitution.

Authors:  C L Clark; P K Cecil; D Singh; D M Gray
Journal:  Nucleic Acids Res       Date:  1997-10-15       Impact factor: 16.971

3.  Effects of oligonucleotide length and atomic composition on stimulation of the ATPase activity of translation initiation factor elF4A.

Authors:  M L Peck; D Herschlag
Journal:  RNA       Date:  1999-09       Impact factor: 4.942

4.  P-stereocontrolled synthesis of oligo(nucleoside N3'→O5' phosphoramidothioate)s - opportunities and limitations.

Authors:  Ewa Radzikowska; Renata Kaczmarek; Dariusz Korczyński; Agnieszka Krakowiak; Barbara Mikołajczyk; Janina Baraniak; Piotr Guga; Kraig A Wheeler; Tomasz Pawlak; Barbara Nawrot
Journal:  RSC Adv       Date:  2020-09-23       Impact factor: 4.036

Review 5.  In vivo imaging with oligonucleotides for diagnosis and drug development.

Authors:  B Tavitian
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

6.  Superior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense Inhibitors.

Authors:  Tsuyoshi Yamamoto; Hidenori Yasuhara; Fumito Wada; Mariko Harada-Shiba; Takeshi Imanishi; Satoshi Obika
Journal:  J Nucleic Acids       Date:  2012-09-26

7.  Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.

Authors:  Azeem Saleem; Julian C Matthews; Malcolm Ranson; Sophie Callies; Valérie André; Michael Lahn; Claire Dickinson; Christian Prenant; Gavin Brown; Adam McMahon; Denis C Talbot; Terry Jones; Patricia M Price
Journal:  Theranostics       Date:  2011-06-01       Impact factor: 11.556

8.  Phosphorothioate oligonucleotides, suramin and heparin inhibit DNA-dependent protein kinase activity.

Authors:  Y Hosoi; Y Matsumoto; M Tomita; A Enomoto; A Morita; K Sakai; N Umeda; H-J Zhao; K Nakagawa; T Ono; N Suzuki
Journal:  Br J Cancer       Date:  2002-04-08       Impact factor: 7.640

9.  Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif.

Authors:  Amber Goodchild; Andrew King; Mary Margaret Gozar; Toby Passioura; Carly Tucker; Laurent Rivory
Journal:  Nucleic Acids Res       Date:  2007-06-22       Impact factor: 16.971

10.  Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver.

Authors:  Colton M Miller; Aaron J Donner; Emma E Blank; Andrew W Egger; Brianna M Kellar; Michael E Østergaard; Punit P Seth; Edward N Harris
Journal:  Nucleic Acids Res       Date:  2016-02-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.